Gabexate mesylate | CAS#56974-61-9 | 39492-01-8 | serine protease inhibitor

MedKoo Cat#: 319531 | Name: Gabexate mesylate

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Gabexate is a serine protease inhibitor which is used therapeutically (as gabexate mesilate) in the treatment of pancreatitis, disseminated intravascular coagulation, and as a regional anticoagulant for haemodialysis.

Chemical Structure

Gabexate mesylate

CAS#56974-61-9 (mesylate)

Theoretical Analysis

MedKoo Cat#: 319531

Name: Gabexate mesylate

CAS#: 56974-61-9 (mesylate)

Chemical Formula: C17H27N3O7S

Exact Mass: 0.0000

Molecular Weight: 417.48

Elemental Analysis: C, 48.91; H, 6.52; N, 10.07; O, 26.83; S, 7.68

Price and Availability

Size	Price	Availability
250mg	USD 350.00	2 Weeks
1g	USD 850.00	2 Weeks
5g	USD 1,750.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

56974-61-9 (mesylate) 39492-01-8 (free base)

Synonym

Gabexate mesylate; Gabexate mesilate; Gabexate (mesylate); Gabexate Methanesulfonate; Gabexato mesilato; Arodate; Megacart

IUPAC/Chemical Name

4-[[6-[(Aminoiminomethyl)amino]-1-oxohexyl]oxy]-benzoic acid ethyl ester mesylate

InChi Key

DNTNDFLIKUKKOC-UHFFFAOYSA-N

InChi Code

InChI=1S/C16H23N3O4.CH4O3S/c1-2-22-15(21)12-7-9-13(10-8-12)23-14(20)6-4-3-5-11-19-16(17)18;1-5(2,3)4/h7-10H,2-6,11H2,1H3,(H4,17,18,19);1H3,(H,2,3,4)

SMILES Code

O=C(OCC)C1=CC=C(OC(CCCCCNC(N)=N)=O)C=C1.OS(=O)(C)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO, not in water

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Related CAS# 56974-61-9 ( Gabexat mesylate); 39492-01-8 ( Gabexat free base).

Product Data

Product Data

Instruction

View handling instruction

Biological target:

Gabexate mesylate is a Factor X inhibitor; serine protease inhibitor.

In vitro activity:

GM (gabexate mesylate) prevented CraA-induced bronchial epithelial cell detachment and morphological changes. It had superior and more extensive suppression effects than specific target MAPK inhibitors in CraA-induced mRNA expression of IL-8, monocyte chemotactic protein (MCP) 1, chemokine (C-C motif) ligand 20, and granulocyte-macrophage colony-stimulating factor from the cells in a dose-dependent manner. Reference: J Investig Allergol Clin Immunol. 2014;24(5):338-45. https://pubmed.ncbi.nlm.nih.gov/25345304/

In vivo activity:

The rats of the gabexate group, which were administered 20 mg/kg of gabexate mesilate intraperitoneal daily after 3rd day following SNL, showed a higher PWT than those of the vehicle-treated group during the observation period (P < 0.001). These results indicate that gabexate mesilate attenuate the development of mechanical allodynia induced by SNL. Reference: Korean J Pain. 2020 Jan; 33(1): 30–39. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6944363/

	Solvent	mg/mL	mM
Solubility
	DMSO	69.3	166.07
	DMF	25.0	59.88
	Ethanol	83.0	198.81
	Water	20.3	48.63

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 417.48 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Lee MF, Chang CW, Wang NM, Lin SJ, Chen YH. Serine protease inhibitor gabexate mesilate attenuates american cockroach-induced bronchial damage and inflammatory cytokine release. J Investig Allergol Clin Immunol. 2014;24(5):338-45. PMID: 25345304. 2. Brandi G, Tavolari S, De Rosa F, Di Girolamo S, Agostini V, Barbera MA, Frega G, Biasco G. Antitumoral efficacy of the protease inhibitor gabexate mesilate in colon cancer cells harbouring KRAS, BRAF and PIK3CA mutations. PLoS One. 2012;7(7):e41347. doi: 10.1371/journal.pone.0041347. Epub 2012 Jul 24. PMID: 22911782; PMCID: PMC3404056. 3. Oh SH, Lee HY, Ki YJ, Kim SH, Lim KJ, Jung KT. Gabexate mesilate ameliorates the neuropathic pain in a rat model by inhibition of proinflammatory cytokines and nitric oxide pathway via suppression of nuclear factor-κB. Korean J Pain. 2020 Jan 1;33(1):30-39. doi: 10.3344/kjp.2020.33.1.30. PMID: 31888315; PMCID: PMC6944363. 4. Xie LB, Zeng DY, Wang XD, Lin T, Li YP, Lu YP. Preconditioning with gabexate is superior to inosine for ameliorating acute renal ischemia-reperfusion injury in rats. Transplant Proc. 2014 Jan-Feb;46(1):40-5. doi: 10.1016/j.transproceed.2013.10.037. PMID: 24507023.

In vitro protocol:

In vivo protocol:

1. Oh SH, Lee HY, Ki YJ, Kim SH, Lim KJ, Jung KT. Gabexate mesilate ameliorates the neuropathic pain in a rat model by inhibition of proinflammatory cytokines and nitric oxide pathway via suppression of nuclear factor-κB. Korean J Pain. 2020 Jan 1;33(1):30-39. doi: 10.3344/kjp.2020.33.1.30. PMID: 31888315; PMCID: PMC6944363. 2. Xie LB, Zeng DY, Wang XD, Lin T, Li YP, Lu YP. Preconditioning with gabexate is superior to inosine for ameliorating acute renal ischemia-reperfusion injury in rats. Transplant Proc. 2014 Jan-Feb;46(1):40-5. doi: 10.1016/j.transproceed.2013.10.037. PMID: 24507023.

1: Gao HJ, Song Q, Lv FQ, Wang S, Wang YR, Luo YK, Mei XG, Tang J. A novel thermosensitive in-situ gel of gabexate mesilate for treatment of traumatic pancreatitis: An experimental study. J Huazhong Univ Sci Technolog Med Sci. 2015 Oct;35(5):707-11. doi: 10.1007/s11596-015-1494-2. Epub 2015 Oct 22. PubMed PMID: 26489626. 2: Akahoshi T, Sugimori H, Kaku N, Tokuda K, Nagata T, Noda E, Morita M, Hashizume M, Maehara Y. Comparison of recombinant human thrombomodulin and gabexate mesylate for treatment of disseminated intravascular coagulation (DIC) with sepsis following emergent gastrointestinal surgery: a retrospective study. Eur J Trauma Emerg Surg. 2015 Oct;41(5):531-8. doi: 10.1007/s00068-014-0478-4. Epub 2014 Nov 20. PubMed PMID: 26038004. 3: Tsai HJ, Ding C, Tsao CM, Liao MH, Ka SM, Liaw WJ, Wu CC. Effects of gabexate mesilate on coagulopathy and organ dysfunction in rats with endotoxemia: a potential use of thrombelastography in endotoxin-induced sepsis. Blood Coagul Fibrinolysis. 2015 Mar;26(2):175-84. doi: 10.1097/MBC.0000000000000214. PubMed PMID: 25396762. 4: Carlucci G, Selvaggi F, Sulpizio S, Bassi C, Carlucci M, Cotellese R, Ferrone V, Innocenti P, Locatelli M. Combined derivatization and high-performance liquid chromatography with fluorescence and ultraviolet detection for simultaneous analysis of octreotide and gabexate mesylate metabolite in human pancreatic juice samples. Biomed Chromatogr. 2015 Jun;29(6):911-7. doi: 10.1002/bmc.3373. Epub 2014 Oct 30. PubMed PMID: 25354693. 5: Lee MF, Chang CW, Wang NM, Lin SJ, Chen YH. Serine protease inhibitor gabexate mesilate attenuates american cockroach-induced bronchial damage and inflammatory cytokine release. J Investig Allergol Clin Immunol. 2014;24(5):338-45. PubMed PMID: 25345304. 6: Imberti R, Ferrigno A, Tartaglia A, Rizzo V, Richelmi P, Vairetti M. Changes in extra- and intracellular pH in hepatocytes exposed to gabexate mesilate. Int J Immunopathol Pharmacol. 2014 Jul-Sep;27(3):365-70. PubMed PMID: 25280027. 7: Takazono T, Nakamura S, Imamura Y, Yoshioka S, Miyazaki T, Izumikawa K, Sawai T, Matsuo N, Yanagihara K, Suyama N, Kohno S. A retrospective comparative study of recombinant human thrombomodulin and gabexate mesilate in sepsis-induced disseminated intravascular coagulation patients. J Infect Chemother. 2014 Aug;20(8):484-8. doi: 10.1016/j.jiac.2014.04.010. Epub 2014 May 21. PubMed PMID: 24855912. 8: Xie LB, Zeng DY, Wang XD, Lin T, Li YP, Lu YP. Preconditioning with gabexate is superior to inosine for ameliorating acute renal ischemia-reperfusion injury in rats. Transplant Proc. 2014 Jan-Feb;46(1):40-5. doi: 10.1016/j.transproceed.2013.10.037. PubMed PMID: 24507023. 9: Kim SC, Yang HR. Clinical efficacy of gabexate mesilate for acute pancreatitis in children. Eur J Pediatr. 2013 Nov;172(11):1483-90. doi: 10.1007/s00431-013-2068-6. Epub 2013 Jun 29. PubMed PMID: 23812506. 10: Gigante A, Gasperini ML, Barbano B, Liberatori M, Sardo L, Jovanovic T, Giannakakis K, Cianci R, Amoroso A. Gabexate mesylate as treatment in the course of ANCA-negative microscopic polyangiitis. Ren Fail. 2013;35(5):721-4. doi: 10.3109/0886022X.2013.780620. Epub 2013 Apr 8. PubMed PMID: 23560992. 11: Yasunaga H, Horiguchi H, Hashimoto H, Matsuda S, Fushimi K. Effect and cost of treatment for acute pancreatitis with or without gabexate mesylate: a propensity score analysis using a nationwide administrative database. Pancreas. 2013 Mar;42(2):260-4. doi: 10.1097/MPA.0b013e31826495a0. PubMed PMID: 23000890. 12: Brandi G, Tavolari S, De Rosa F, Di Girolamo S, Agostini V, Barbera MA, Frega G, Biasco G. Antitumoral efficacy of the protease inhibitor gabexate mesilate in colon cancer cells harbouring KRAS, BRAF and PIK3CA mutations. PLoS One. 2012;7(7):e41347. doi: 10.1371/journal.pone.0041347. Epub 2012 Jul 24. PubMed PMID: 22911782; PubMed Central PMCID: PMC3404056. 13: Noguchi H, Naziruddin B, Jackson A, Shimoda M, Fujita Y, Chujo D, Takita M, Peng H, Sugimoto K, Itoh T, Kobayashi N, Ueda M, Okitsu T, Iwanaga Y, Nagata H, Liu X, Kamiya H, Onaca N, Levy MF, Matsumoto S. Comparison of ulinastatin, gabexate mesilate, and nafamostat mesilate in preservation solution for islet isolation. Cell Transplant. 2012;21(2-3):509-16. doi: 10.3727/096368911X605420. PubMed PMID: 22793059. 14: Yoo YW, Cha SW, Kim A, Na SY, Lee YW, Kim SH, Lee HIe, Lee YJ, Yang HW, Jung SH. The use of gabexate mesylate and ulinastatin for the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis. Gut Liver. 2012 Apr;6(2):256-61. doi: 10.5009/gnl.2012.6.2.256. Epub 2012 Apr 17. PubMed PMID: 22570757; PubMed Central PMCID: PMC3343166. 15: Kwon YH, Kim JY, Lee SJ, Jang SY, Park HW, Yang HM, Jung MK, Jeon SW, Cho CM, Tak WY, Kweon YO, Kim SK. [Could nafamostat or gabexate prevent the post endoscopic retrograde cholangiopancreatography pancreatitis?]. Korean J Gastroenterol. 2012 Mar;59(3):232-8. Korean. PubMed PMID: 22460572. 16: Nishiyama T, Kohno Y, Koishi K. Effects of antithrombin and gabexate mesilate on disseminated intravascular coagulation: a preliminary study. Am J Emerg Med. 2012 Sep;30(7):1219-23. doi: 10.1016/j.ajem.2011.06.003. Epub 2011 Dec 26. PubMed PMID: 22204993. 17: Tokodai K, Goto M, Inagaki A, Imura T, Satomi S. Effect of synthetic protease inhibitor gabexate mesilate on attenuation of coagulant activity and cytokine release in a rat model of islet transplantation. Transplant Proc. 2011 Nov;43(9):3176-8. doi: 10.1016/j.transproceed.2011.10.035. PubMed PMID: 22099749. 18: Horiuchi A, Watanabe Y, Sato K, Yoshida M, Yamamoto Y, Sugishita H, Kameoka K, Kawachi K. Continuous irrigation with gabexate mesilate around pancreaticojejunostomy after pancreaticoduodenectomy. Hepatogastroenterology. 2010 Sep-Oct;57(102-103):1291-4. PubMed PMID: 21410074. 19: Kumura T, Aoyama Y, Ichihara H, Koh S, Mugitani A, Hayakawa H, Yukioka K, Kinoshita D, Nakagawa M, Yamazaki N. [Successful treatment with the combination of recombinant human soluble thrombomodulin and gabexate mesilate in three patients with obstetric disseminated intravascular coagulation]. Rinsho Ketsueki. 2011 Feb;52(2):68-72. Japanese. PubMed PMID: 21403426. 20: Miyagi S, Enomoto Y, Sekiguchi S, Kawagishi N, Satomi S. The effects of gabexate mesilate on the microsurgical reconstruction of the hepatic artery in living donor liver transplantation. Transplant Proc. 2010 Dec;42(10):4158-60. doi: 10.1016/j.transproceed.2010.10.007. PubMed PMID: 21168651.